Search research articles
Contact Us
Filters
Showing results (81-90 of 122) with videos related to
Page
of 13
Sort By:
Seminars in Oncology
|
June 10, 2025
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population
Francesco Vitiello, Toshifumi Tada, Goki Suda, et al.
Liver Cancer
|
August 11, 2022
Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study
Sabrina Welland, Catherine Leyh, Fabian Finkelmeier, et al.
Theranostics
|
May 1, 2019
Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse Sepsis
Andreas von Knethen, Anne Schäfer, Laura Kuchler, et al.
Annals of Hepatology
|
August 15, 2024
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma
Louisa Stern, Constantin Schmidt, Lorenz Kocheise, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 2, 2026
Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab
Andrea Casadei-Gardini, Terry Cheuk-Fung Yip, Alessandro Vitale, et al.
Biochemical and Biophysical Research Communications
|
July 21, 2024
The TGF-β1 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro- and anti-tumorigenic effects
Anne Dropmann, Sophie Alex, Katharina Schorn, et al.
European Journal of Clinical Investigation
|
July 6, 2023
Unveiling the diagnostic enigma of D-dimer testing in cancer patients: Current evidence and areas of application
Jennifer Gotta, Leon D Gruenewald, Katrin Eichler, et al.
JHEP Reports : Innovation in Hepatology
|
April 30, 2026
Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC
Najib Ben Khaled, Raphael Mohr, Leonie S Jochheim, et al.
Alimentary Pharmacology & Therapeutics
|
February 28, 2024
Terlipressin therapy is associated with increased risk of colonisation with multidrug-resistant bacteria in patients with decompensated cirrhosis
Marcus M Mücke, María Hernández-Tejero, Wenyi Gu, et al.
Gastroenterology
|
September 15, 2022
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
Philipp K Haber, Florian Castet, Miguel Torres-Martin, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 122) with videos related to
Sort By:
Page
of 13
Seminars in Oncology
|
June 10, 2025
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population
Francesco Vitiello, Toshifumi Tada, Goki Suda, et al.
Liver Cancer
|
August 11, 2022
Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study
Sabrina Welland, Catherine Leyh, Fabian Finkelmeier, et al.
Theranostics
|
May 1, 2019
Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse Sepsis
Andreas von Knethen, Anne Schäfer, Laura Kuchler, et al.
Annals of Hepatology
|
August 15, 2024
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma
Louisa Stern, Constantin Schmidt, Lorenz Kocheise, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 2, 2026
Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab
Andrea Casadei-Gardini, Terry Cheuk-Fung Yip, Alessandro Vitale, et al.
Biochemical and Biophysical Research Communications
|
July 21, 2024
The TGF-β1 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro- and anti-tumorigenic effects
Anne Dropmann, Sophie Alex, Katharina Schorn, et al.
European Journal of Clinical Investigation
|
July 6, 2023
Unveiling the diagnostic enigma of D-dimer testing in cancer patients: Current evidence and areas of application
Jennifer Gotta, Leon D Gruenewald, Katrin Eichler, et al.
JHEP Reports : Innovation in Hepatology
|
April 30, 2026
Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC
Najib Ben Khaled, Raphael Mohr, Leonie S Jochheim, et al.
Alimentary Pharmacology & Therapeutics
|
February 28, 2024
Terlipressin therapy is associated with increased risk of colonisation with multidrug-resistant bacteria in patients with decompensated cirrhosis
Marcus M Mücke, María Hernández-Tejero, Wenyi Gu, et al.
Gastroenterology
|
September 15, 2022
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
Philipp K Haber, Florian Castet, Miguel Torres-Martin, et al.
Page
of 13